Syneos Health - SYNH Stock Forecast, Price & News

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on SYNH shares. Robert W. Baird reduced their target price on shares of Syneos Health to $89.00 in a report on Tuesday, August 9th. Jefferies Financial Group lowered shares of Syneos Health from a "buy" rating to a "hold" rating and reduced their price objective for the company from $101.00 to $75.00 in a research note on Monday, April 25th. Guggenheim assumed coverage on shares of Syneos Health in a research note on Monday, May 23rd. They issued a "buy" rating and a $81.00 price objective on the stock. Barclays reduced their price objective on shares of Syneos Health from $90.00 to $80.00 in a research note on Wednesday, August 3rd. Finally, Citigroup reduced their price objective on shares of Syneos Health from $80.00 to $70.00 in a research note on Wednesday, August 3rd. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $84.67.

Syneos Health Stock Performance

SYNH opened at $68.88 on Friday. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.86. The company's fifty day moving average price is $71.04 and its two-hundred day moving average price is $75.92. Syneos Health has a 1-year low of $62.28 and a 1-year high of $104.18. The company has a market cap of $7.07 billion, a price-to-earnings ratio of 25.89 and a beta of 1.68.

Syneos Health (NASDAQ:SYNH - Get Rating) last announced its earnings results on Tuesday, August 2nd. The company reported $1.25 EPS for the quarter, beating the consensus estimate of $1.08 by $0.17. Syneos Health had a net margin of 5.13% and a return on equity of 14.04%. The company had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.39 billion. During the same quarter in the prior year, the company posted $0.86 earnings per share. The firm's revenue for the quarter was up 6.0% on a year-over-year basis. On average, analysts expect that Syneos Health will post 4.54 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Michelle Keefe sold 8,333 shares of the firm's stock in a transaction that occurred on Monday, July 18th. The shares were sold at an average price of $72.81, for a total value of $606,725.73. Following the sale, the chief executive officer now directly owns 71,266 shares of the company's stock, valued at $5,188,877.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Syneos Health news, CEO Michelle Keefe sold 8,333 shares of Syneos Health stock in a transaction that occurred on Monday, July 18th. The shares were sold at an average price of $72.81, for a total transaction of $606,725.73. Following the transaction, the chief executive officer now directly owns 71,266 shares of the company's stock, valued at $5,188,877.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Jonathan Olefson sold 2,215 shares of Syneos Health stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $75.00, for a total transaction of $166,125.00. Following the completion of the transaction, the general counsel now directly owns 25,292 shares in the company, valued at $1,896,900. The disclosure for this sale can be found here. Insiders sold 22,403 shares of company stock worth $1,646,313 over the last quarter. 0.34% of the stock is currently owned by company insiders.